



INDIANA UNIVERSITY

**MELVIN AND BREN SIMON  
COMPREHENSIVE CANCER CENTER**

**Cancer center member participation at the  
American Society of Clinical Oncology (ASCO)  
Annual Meeting 2021**

**June 4 - June 8, 2021**

Members indicated in **BOLD**

**ORAL ABSTRACT SESSIONS**

---

**Late relapse of germ cell tumors: Detection and treatment outcomes.**

Oral abstract session | Abstract: 5007 | Session track: Genitourinary Cancer—Prostate, Testicular, and Penile, Subtrack: [Biomarkers/Imaging/Epidemiology/Outcomes](#)

**Authors:** Noah Hunter Richardson, Sandra K. Althouse, Ryan Ashkar, **Clint Cary**, **Timothy A. Masterson**, Richard Foster, **Nasser H. Hanna**, **Lawrence H. Einhorn**, **Nabil Adra**; Indiana University Department of Medicine, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN

---

**Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy.**

Oral abstract session | Abstract: 12004 | Track: Symptoms and Survivorship, [Late and Long-Term Effects](#)

**Authors:** Xindi Zhang, Matthew R. Trendowski, Emma Wilkinson, Darren R. Feldman, Robert James Hamilton, David J. Vaughn, Chunkit Fung, Christian K. Kollmannsberger, Robert A Huddart, Neil E. Martin, Paul C Dinh, Robert D. Frisina, **Lawrence H. Einhorn**, M. Eileen Dolan, **Lois B. Travis**; Regeneron Genetics Center; Department of Medicine, University of Chicago, Chicago, IL; Department of Medicine, The University of Chicago, Chicago, IL; Memorial Sloan Kettering Cancer Center, New York, NY; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Pennsylvania, Philadelphia, PA; J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Dana-Farber Cancer Institute/Brigham & Women's Hospital, Boston, MA; Indiana University School of Medicine, Indianapolis, IN; Departments of Medical Engineering and Communication Sciences and Disorders, Global

**A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131**

Oral abstract session | Abstract: 605 | Track: Breast Cancer—Local/Regional/Adjuvant, [Neoadjuvant Therapy](#)

**Authors:** Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, William Fraser Symmans, Ben Ho Park, Brian Leslie Burnette, Amye Juliet Tevaarwerk, Sofia F. Garcia, Karen L. Smith, Erica L. Mayer, William M. Sikov, Eve T. Rodler, Lynne I. Wagner, Angela DeMichele, Joseph A. Sparano, Antonio C. Wolff, **Kathy Miller**; Vanderbilt University, Nashville, TN; Dana–Farber Cancer Institute, Malden, MA; Vanderbilt University Ingram Cancer Center, Nashville, TN; The University of Texas MD Anderson Cancer Center, Houston, TX; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Cancer Research of Wisconsin and Northern Michigan (CROWN) NCORP, Green Bay, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; Northwestern University Feinberg School of Medicine, Chicago, IL; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; Women and Infants Hospital of Rhode Island, Providence, RI; Fremont-Rideout Cancer Center, Marysville, CA; Wake Forest University Health Sciences, Winston-Salem, NC; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY; Indiana University Simon Cancer Center Indianapolis, Indianapolis, IN

---

**Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.**

Oral abstract session | Abstract: 12003 | Track: Symptoms and Survivorship, [Late and Long-Term Effects](#)

**Authors:** Vered Stearns, Opeyemi Jegede, Victor Tsu-Shih Chang, **Todd C. Skaar**, Jeffrey L. Berenberg, Ranveer Nand, Alan P. Lyss, Nisha Lassi Jacobs, William E. Luginbuhl, Paul Gilman, Al Benson, Judie R. Goodman, Gary L Buchschacher, Norah Lynn Henry, Charles L. Loprinzi, Patrick J. Flynn, Edith P. Mitchell, Michael Jordan Fisch, Joseph A. Sparano, Lynne I. Wagner; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, Baltimore, MD; Dana Farber Cancer Institute, Boston, MA; Section of Hematology/Oncology, Veterans Administration New Jersey Health Care System, East Orange, NJ; Indiana University School of Medicine, Indianapolis, MD; University of Hawaii Cancer Center, Honolulu, HI; Columbia Saint Mary's Hospital, Milwaukee, WI; Missouri Baptist Medical Center, Saint Louis, MO; Minnesota Oncology Hematology, Minneapolis, MN; Chester County Hospital, Chester, PA; Main Line Oncology Hematology Associates, Wynnewood, PA; Northwestern Medicine, Chicago, IL; Saint Joseph Mercy Oakland, Pontiac, MI; Southern California Permanente Medical Group, Los Angeles, CA; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Abbott-Northwestern Hospital, Woodbury, MN; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; AIM Specialty Health, Chicago, IL; Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY; Wake Forest University Health Sciences, Winston-Salem, NC

---

## CLINICAL SCIENCE SYMPOSIUM

---

### Impact of African ancestry on the relationship between BMI and survival in early stage breast cancer: Retrospective analysis from E5103.

Clinical Science Symposium | Abstract: 1010 | Session track: Breast Cancer—  
Local/Regional/Adjuvant, [Biologic Correlates](#)

**Authors:** **Tarah Jean Ballinger**, Guanglong Jiang, Fei Shen, **Kathy Miller**, **Bryan P. Schneider**; Indiana University, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Indiana University Simon Cancer Center Indianapolis, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN

---

### Novel approach to improve the diagnosis of pediatric cancer in Kenya via telehealth education.

Clinical Science Symposium | Abstract: 11000 | Session track: Professional Development and Education Advances, [Education Research](#)

**Authors:** Tyler Severance, Gilbert Kipruto Olbara, Festus Njuguna, Marjorie Treff, **Patrick J. Loehrer**, **Terry A. Vik**; Riley Hospital for Children, Division of Pediatric Hematology Oncology, Indianapolis, IN; Moi University School of Medicine, Eldoret, Kenya; Indiana University, W.W. Wright School of Education, Bloomington, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN

---

## POSTER DISCUSSION SESSIONS

---

### Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT).

Poster discussion session | Abstract: 5018 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile, [Germ Cell/Testicular](#)

**Authors:** Jennifer King, Sandra K. Althouse, **Clint Cary**, **Timothy A. Masterson**, Richard Foster, Ryan Ashkar, **Nasser H. Hanna**, **Lawrence H. Einhorn**, **Nabil Adra**; Indiana University School of Medicine, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

---

**Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.**

Poster discussion session | Abstract: 5016 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile, [Germ Cell/Testicular](#)

**Authors:** Shirin Ardeshirrouhanifard, Sophie Fosså, Robert A Huddart, **Patrick O. Monahan**, Chunkit Fung, Yiqing Song, M. Eileen Dolan, Darren R. Feldman, Robert James Hamilton, David J. Vaughn, Neil E. Martin, Christian K. Kollmannsberger, Paul C Dinh, Lifang Hou, Yinan Zheng, **Lawrence Einhorn**, Robert D. Frisina, **Lois B. Travis**; Indiana University School of Medicine, Indianapolis, IN; National Advisory Unit on Late Effects After Cancer Treatment, Oslo, Norway; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; Indiana University Richard M Fairbanks School of Public Health, Indianapolis, IN; Department of Medicine, University of Chicago, Chicago, IL; Memorial Sloan Kettering Cancer Center, New York, NY; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Pennsylvania, Philadelphia, PA; Dana Farber Cancer Institute, Boston, MA; Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada; Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University, Chicago, IL; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Departments of Medical Engineering and Communication Sciences and Disorders, Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL

---

**Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy.**

Poster discussion session | Abstract: 5019 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile, [Germ Cell/Testicular](#)

**Authors:** Andreas Georg Wibmer, Darren R. Feldman, Carol Chen, Maria Bromberg, Paul C Dinh, Junting Zheng, Marinela Capanu, **Lois B. Travis**, Hebert Alberto Vargas; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; Indiana University School of Medicine, Indianapolis, IN

---

**Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.**

Poster discussion session | Abstract: 520 | Track: Breast Cancer—Local/Regional/Adjuvant, [Biologic Correlates](#)

**Authors:** Joseph A. Sparano, Anne M. O'Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff, George W. Sledge, **Kathy Miller**; Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY; Dana-Farber Cancer Institute, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Mayo Clinic, Phoenix, AZ; Memorial Sloan Kettering Cancer Center, New York, NY; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Stanford University School of Medicine, Stanford, CA; Indiana University Simon Cancer Center Indianapolis, Indianapolis, IN

---

## POSTER SESSIONS

---

### **A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study.**

Poster session | Abstract: 8570 | Track: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers, [Small Cell Lung Cancer](#)

**Authors:** Jyoti Malhotra, **Nasser H. Hanna**, Alberto Chiappori, Lawrence Eric Feldman, Naomi Fujioka, Igor I. Rybkin, **Shadia Ibrahim Jalal**, Malini Patel, Dirk Moore, Chunxia Chen, Salma K. Jabbour; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; University of Illinois Hospital & Health Sciences System, Chicago, IL; Univ of Minnesota, Minneapolis, MN; Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI; Indiana University Simon Cancer Center, Indianapolis, IN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Biometrics, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ

---

### **Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Early results from a multicenter phase I trial.**

Poster session | Abstract: 2025 | Session track: Central Nervous System Tumors, [Brain Metastases](#)

**Authors:** Shearwood McClelland, **Tim Lautenschlaeger**, Kevin Shiue, Amy C. Miller, Yong Zang, Kathryn I. Lauer, **Nasser H. Hanna**, Ryan Rhome, Namita Agrawal, Paul Anthony, Mu Shan, Jerry Jeff Jaboin, Gordon A Watson; Indiana University School of Medicine, Indianapolis, IN; Indiana University School of Medicine, Dept of Radiation Oncology, Indianapolis, IN; Department of Radiation Oncology, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN; Indiana University Department of Biostatistics, Indianapolis, IN; Indiana University, Department of Radiation Oncology, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University Department of Radiation Oncology, Indianapolis, IN; Indiana University, Indianapolis, IN; Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN; Department of Radiation Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR

---

### **Clinicogenomic characterization of metastatic thymic epithelial tumors.**

Poster session | Abstract: 8579 | Session track: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers, [Thymic Malignancies](#)

**Authors:** Fatemeh Ardeshir-Larijani, **Milan Radovich**, **Bryan P. Schneider**, **Patrick J. Loehrer**; Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

---

---

**A comprehensive literature review and meta-analysis on prognostic value of BRCAm, HRRm and HRD+ across tumor types.**

Poster session | Abstract: 3125 | Session track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology, [Tissue-Based Biomarkers](#)

**Authors:** Changxia Shao, Andrew Marley, Huilin Tang, **Jun Wan**, Chelsey Miller, Madeline Brown, Yiqing Song, **Jiali Han**, Gboyega Adeboyeje; Merck & Co., Inc., Kenilworth, NJ; Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, IN; Integrative Precision Health LLC, Carmel, IN; Indiana University School of Medicine, Indianapolis, IN; Indiana University Richard M Fairbanks School of Public Health, Indianapolis, IN

---

**A comprehensive literature review and meta-analysis on prevalence of BRCAm, HRRm and HRD+ across tumor types.**

Poster session | Abstract: 10589 | Session track: Prevention, Risk Reduction, and Hereditary Cancer, [Genetic Testing](#)

**Authors:** Changxia Shao, Jun Wan, Huilin Tang, Andrew Marley, Chelsey Miller, Madeline Brown, Yiqing Song, **Jiali Han**, Gboyega Adeboyeje; Merck & Co., Inc., Kenilworth, NJ; Indiana University School of Medicine, Indianapolis, IN; Integrative Precision Health LLC, Carmel, IN; Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, IN; Indiana University Richard M Fairbanks School of Public Health, Indianapolis, IN

---

**Outcomes of patients with germ cell tumors diagnosed with stage I disease who subsequently received high dose chemotherapy (HDCT) with peripheral stem cell transplant (PBSCT) following failure of initial therapy for metastatic disease: The Indiana University experience.**

Poster session | Abstract: 5029 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile, [Germ Cell/Testicular](#)

**Authors:** Stephen B Benzinger, Ryan Ashkar, **Rafat Abonour**, **Mohammad Issam Abu Zaid**, **Nabil Adra**, **Lawrence H. Einhorn**, **Nasser H. Hanna**; Indiana University School of Medicine, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

**Adjuvant chemotherapy with CAV/IE for malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): An institutional analysis from Indiana University.**

Poster session | Abstract: 5026 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile, [Germ Cell/Testicular](#)

**Authors:** Cynthia Wei, **Clint Cary**, **Timothy A. Masterson**, Richard Foster, Ryan Ashkar, **Nabil Adra**, **Nasser H. Hanna**, **Lawrence H. Einhorn**; Indiana University School of Medicine, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

---

**A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.**

Poster session | Abstract: 9073 | Track: Lung Cancer—Non-Small Cell Metastatic, [Metastatic Non-Small Cell Lung Cancer](#)

**Authors:** Nikhil Shukla, Sandra K. Althouse, Susan Perkins, Muhammad Furqan, Ticiana Leal, **Nasser H. Hanna**, **Greg Andrew Durm**; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University, Indianapolis, IN; University of Iowa Hospitals and Clinics, Iowa City, IA; University of Wisconsin Carbone Cancer Center, Madison, WI

---

**Social determinants of health, genetic ancestry, and mortality in ECOG-ACRIN E5103.**

Poster session | Abstract: 6527 | Track: Health Services Research and Quality Improvement, [Disparities/Access to Care](#)

**Authors:** Samilia Obeng-Gyasi, Anne M. O'Neill, **Kathy Miller**, **Bryan P. Schneider**, Ann H. Partridge, Lava R Timsina, George W. Sledge, Lynne I. Wagner, Ruth Carlos; The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; Indiana University Simon Cancer Center Indianapolis, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Stanford University School of Medicine, Stanford, CA; Wake Forest University Health Sciences, Winston-Salem, NC; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

---

**Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.**

Poster session | Abstract: 9034 | Track: Lung Cancer—Non-Small Cell Metastatic, [Metastatic Non-Small Cell Lung Cancer](#)



**Authors:** Fatemeh Ardeshir-Larijani, Sandra K. Althouse, Ticiana Leal, Lawrence Eric Feldman, Taher Abu Hejleh, Malini Patel, Ryan D. Gentzler, Adam Ryan Miller, **Nasser H. Hanna**; Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Illinois Hospital & Health Sciences System, Chicago, IL; University of Iowa Hospitals and Clinics, Iowa City, IA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Virginia Cancer Center, Charlottesville, VA; Indiana University School of Medicine, Winchester, MA

---

**Impact of a sustainable breast and cervical cancer screening program in spite of COVID-19 pandemic: The AMPATH experience in Kenya.**

Poster session | Abstract: 10556 | Track: Prevention, Risk Reduction, and Hereditary Cancer, [Cancer Prevention](#)

**Authors:** Stephen Kiptoo, Naftali Wisindi Busakhala, Peter Itsura, Philip Tonui, **Terry Vik, Patrick J. Loehrer**, Omenge Elkanah Orang'o; AMPATH Oncology, Eldoret, Kenya; Teaching and Referral Hospital, Eldoret, Rift Valley, Kenya; Eldoret Teaching and Referral Hospital, Eldoret, Kenya; Indiana University, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Moi University College of Health Sciences, Eldoret, Kenya

---

**A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.**

Poster session | Abstract: TPS8583 | Track: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers, [Adjuvant Therapy](#)

**Authors:** **Greg Andrew Durm**, Muhammad Furqan, Lawrence Eric Feldman, Malini Patel, Richard Delmar Hall, **Shadia Ibrahim Jalal**, Thomas J. Birdas, Kenneth Kesler, Karen Marie Rieger, **DuyKhanh Ceppa**, **Nasser H. Hanna**; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; University of Iowa Hospitals and Clinics, Iowa City, IA; University of Illinois Hospital & Health Sciences System, Chicago, IL; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Virginia, Charlottesville, VA; Indiana University Dept of Cardiosurgery, Indianapolis, IN

---

**Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.**

Poster session | Abstract: 5025 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile, [Germ Cell/Testicular](#)

**Authors:** Shirin Ardeshirrouhanifard, Paul C Dinh, **Patrick O. Monahan**, Sophie Fosså, Robert A Huddart, Chunkit Fung, Yiqing Song, Darren R. Feldman, Robert James Hamilton, David J. Vaughn, Neil E. Martin, Christian K. Kollmannsberger, Lifang Hou, **Lawrence Einhorn**, Kurt Kroenke, **Lois B. Travis**; Indiana University School of Medicine, Indianapolis, IN; National Advisory Unit on



Late Effects After Cancer Treatment, Oslo, Norway; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; Indiana University Richard M Fairbanks School of Public Health, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, New York, NY; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Pennsylvania, Philadelphia, PA; Dana Farber Cancer Institute, Boston, MA; Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada; Feinberg School of Medicine, Northwestern University, Chicago, IL; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN

---

**Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.**

Poster session | Abstract: 12063 | Track: Symptoms and Survivorship, [Late and Long-Term Effects](#)

**Authors:** Megan Shuey, Annika Faucon, Matthew R. Trendowski, Mark J. Ratain, Paul C Dinh, Darren R. Feldman, Robert James Hamilton, David J. Vaughn, Chunkit Fung, Christian K. Kollmannsberger, Robert A Huddart, Neil E. Martin, Robyn Hannigan, **Lawrence H. Einhorn**, **Lois B. Travis**, M. Eileen Dolan, Nancy Cox; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Department of Medicine, The University of Chicago, Chicago, IL; University of Chicago, Chicago, IL; Indiana University School of Medicine, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, New York, NY; Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Pennsylvania, Philadelphia, PA; J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Dana Farber Cancer Institute, Boston, MA; Clarkson University, Potsdam, NY; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Department of Medicine, University of Chicago, Chicago, IL

---

**Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.**

Poster session | Abstract: TPS1111 | Track: Breast Cancer—Metastatic, [Other/Nonsubtype Specific](#)

**Authors:** Neelima Vidula, Rita Nanda, **Kathy D. Miller**, Leisha A. Emens, Paula R Pohlmann, Vandana G Abramson, Ben Ho Park, Minetta C. Liu, Andrei Goga, Hope S. Rugo; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vanderbilt-Ingram Cancer Center, Nashville, TN; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Mayo Clinic, Rochester, MN; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of California, San Francisco, San Francisco, CA

---

**Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).**

Poster session | Abstract: 5040 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile, [Prostate Cancer - Advanced/Castrate-Resistant](#)

**Authors:** Christopher T Su, Emily Nizialek, Jacob E Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova, Pedro C. Barata, Rahul Raj Aggarwal, Heather McClure, Nellie Nafissi, Alan Haruo Bryce, A. Oliver Sartor, Heather H. Cheng, **Nabil Adra**, Cora N. Sternberg, Mary-Ellen Taplin, Marcin Cieslik, Emmanuel S. Antonarakis, Ajjai Shivaram Alva; University of Michigan Rogel Cancer Center, Ann Arbor, MI; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; Weill Cornell Medicine, New York, NY; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; University of Washington, Seattle, WA; Tulane Cancer Center, New Orleans, LA; University of California, San Francisco, San Francisco, CA; Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic, Phoenix, AZ

---

**A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).**

Poster session | Abstract: TPS4170 | Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary, [Pancreatic Cancer](#)

**Authors:** Sherise C. Rogers, Brian Hemendra Ramnarain, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Z. Hugh Fan, Carmen Joseph Allegra, Jose Trevino, Ahmad El-Far, **Anita Ahmed Turk**, Karen Bullock Russell, David L. DeRemer, Thomas J. George; University of Florida/UF Health Cancer Center, Gainesville, FL; University of Florida, Gainesville, FL; NSABP/NRG Oncology, and The University of Florida Health, Gainesville, FL; University of Florida Health Cancer Center, Gainesville, FL; University of Florida Health Cancer Center—Orlando Health, Orlando, FL; Department of Medicine, Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, IN; Tallahassee Memorial Hospital, Tallahassee, FL; NRG Oncology, and The University of Florida Health Cancer Center, Gainesville, FL

---

**Engaging the radiology community in the National Clinical Trials Network: The ECOG-ACRIN TMIST experience.**

Poster session | Abstract: TPS10609 | Track: Prevention, Risk Reduction, and Hereditary Cancer, [Cancer Prevention](#)

**Authors:** Etta Pisano, Constantine Gatsonis, Mitchell D. Schnall, Martin Yaffe, Melissa A. Troester, Ilana F. Gareen, Laura C. Collins, Amarinthia Curtis, Elodia Cole, Jean Cormack, Ruth Carlos, **Kathy Miller**, Christopher Comstock; Beth Israel Deaconess Medical Center, Boston, MA; Brown University, Providence, RI; Hosp of the Univ of Penn, Philadelphia, PA; Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; University of North Carolina-Chapel Hill, Chapel Hill, NC; Brown University—ECOG-ACRIN Biostatistics Center, Providence, RI; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Spartanburg Medical Center, Gibbs Cancer Center, Spartanburg, SC; American College of Radiology, Philadelphia, PA; Brown University Center for Statistical Science, Providence, RI; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Indiana University Simon Cancer Center Indianapolis, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, New York, NY

---

**Physician concern about delaying lung cancer treatment while awaiting biomarker testing: Results of a survey of U.S. oncologists.**

Poster session | Abstract: 9067 | Track: Lung Cancer—Non-Small Cell Metastatic, [Metastatic Non-Small Cell Lung Cancer](#)

**Authors:** Kathryn Finch Mileham, Upal Kunal Basu Roy, Suanna Steeby Bruinooge, Janet Freeman-Daily, Edward B. Garon, Liz Garrett-Mayer, **Shadia Ibrahim Jalal**, Bruce E. Johnson, Amy Moore, Raymond U. Osarogiagbon, Lauren Rosenthal, Caroline Schenkel, Robert A. Smith, Shamsuddin Virani, Mary Weber Redman, Gerard A. Silvestri; Levine Cancer Institute/Atrium Health, Charlotte, NC; LUNGevery, Bethesda, MD; American Society of Clinical Oncology, Alexandria, VA; Gray Connections, Federal Way, WA; University of California, Los Angeles, Los Angeles, CA; Indiana University Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; Bonnie J Addario Lung Cancer Foundation, San Carlos, CA; Baptist Cancer Center, Multidisciplinary Thoracic Oncology Department, Memphis, TN; American Cancer Society, Atlanta, GA; Aurora Cancer Care-Southern Lakes VLCC, Burlington, WI; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Medical University of South Carolina, Charleston, SC

---

**Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreak 101).**

Poster session | Abstract: TPS2669 | Track: Developmental Therapeutics—Immunotherapy, [New Targets and New Technologies \(IO\)](#)

**Authors:** David S. Hong, John H. Strickler, Marwan Fakih, Gerald Steven Falchook, Bob T. Li, **Greg Andrew Durm**, Timothy F. Burns, Suresh S. Ramalingam, Sarah B. Goldberg, Richard C. Frank, Kristen Marrone, Catherine A. Shu, David R. Gandara, Neelesh Soman, Haby Adel Henary, Ramaswamy Govindan; The University of Texas MD Anderson Cancer Center, Houston, TX; Duke University School of Medicine, Durham, NC; City of Hope Comprehensive Medical Center, Duarte, CA; Sarah Cannon Research Institute, Denver, CO; Memorial Sloan Kettering Cancer Center, New York, NY; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Winship Cancer Institute of Emory University, Atlanta, GA; Yale School of Medicine, New Haven, CT; Nuvance Health, Norwalk, CT; Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Columbia University Medical Center, New York, NY; University of California Davis Comprehensive Cancer Center, Sacramento, CA; Translational Medicine, Amgen Inc., Thousand Oaks, CA; Amgen Inc., Thousand Oaks, CA; Washington University School of Medicine, St. Louis, MO

---

**Predictors of surgery preference and quality of life in DCIS after breast MRI: A trial of the ECOG-ACRIN Cancer Research Group (E4112).**

Poster session | Abstract: 6465 | Track: Health Services Research and Quality Improvement, [Outcomes](#)

**Authors:** Soudabeh Fazeli, Bradley Snyder, Ilana F. Gareen, Constance Dobbins Lehman, Seema Ahsan Khan, Justin Romanoff, Constantine Gatsonis, Ralph L Corsetti, Habib Rahbar, Derrick W. Spell, Kenneth Bruce Blankstein, Linda K. Han, Jennifer L. Sabol, John R Bumberry, **Kathy Miller**, Joseph A. Sparano, Christopher Comstock, Lynne I. Wagner, Ruth Carlos; University of California San Diego Medical Center, San Diego, CA; Brown University, Providence, RI; Brown

University–ECOG-ACRIN Biostatistics Center, Providence, RI; Massachusetts General Hospital, Boston, MA; Northwestern Memorial Hospital, Chicago, IL; Center for Statistical Sciences, Brown University School of Public Health, Providence, RI; Oscher Medical Center Jefferson, New Orleans, LA; University of Washington Seattle Cancer Care Alliance, Seattle, WA; Louisiana Hem Onc Assocs, Baton Rouge, LA; Hunterdon Hematology Oncology, Flemington, NJ; Indiana Univ Simon Cancer Ctr, Indianapolis, IN; Main Line Surgeons, Lankenau Hospital, Wynnewood, PA; Mercy Hospital Springfield, Springfield, MO; Indiana University Simon Cancer Center Indianapolis, Indianapolis, IN; Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Wake Forest University Health Sciences, Winston-Salem, NC; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

## PUBLICATION ONLY

---

### **Prevalence of the concurrent administration of contraindicated medications in patients with cancer treated with tyrosine kinase inhibitors (TKIs): A pilot study from the IU Simon Comprehensive Cancer Center.**

Publication only | Abstract: e18714 | Track: Health Services Research and Quality Improvement, [Real-World Data](#)

**Authors:** Dana Alhaffar, Yan Han, Julianne Darling, **Todd C. Skaar**, Christopher A. Fausel, **Nasser H. Hanna**; Indiana University, Fishers, IN; Indiana University, Indianapolis, IN; National Community Oncology Dispensing Association, Cranbury, NJ; Indiana University School of Medicine, Indianapolis, MD; Indiana Univ Simon Cancer Ctr, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

---

### **Factors associated with cancer screening adherence amongst Latinos in Indiana: Results of an electronic survey.**

Publication only | Abstract: e22513 | Track: Prevention, Risk Reduction, and Hereditary Cancer, [Cancer Prevention](#)

**Authors:** Manuel Ricardo Espinoza Gutarra, **Susan M. Rawl**, Robin E. Valenzuela, Erik Parker, Lilian Golzarri-Arroyo, Malloy L. Caeli, Tisha R. Reid, Laura A. Hauernt, **Heather A. O'Leary**, Gerardo Maupome, **David A. Haggstrom**; Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis, IN; Indiana University School of Nursing, Indianapolis, IN; Indiana University Purdue-Fort Wayne, Fort Wayne, IN; Department of Epidemiology and Biostatistics, School Public Health, Indiana University-Bloomington, Bloomington, IN; Indiana Clinical and Translational Sciences Institute, Indianapolis, IN; Indiana University School of Public Health, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Center for Health Services Research, Regenstrief Institute, Indianapolis, IN

---

### **Tobacco use, knowledge of harms, and cessation support among patients with non-tobacco related cancers.**

Publication only | Abstract: e24029 | Track: Symptoms and Survivorship, [Health Promotion](#)

**Authors:** Laura Vater, Anup Trikannad Ashwini Kumar, Neha Sehgal, Maria Khan, Kelsey Bullens, **Karen S. Hudmon**, Deborah Buckles, Hao Liu, **Nasser H. Hanna**, Girish

Kunapareddy; Indiana University, Indianapolis, IN; Marian University College of Osteopathic Medicine, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Hux Cancer Center, Terre Haute, IN

---

**Patient-reported barriers to online meetings: The case of a myeloma support group in western Kenya in the era of COVID-19.**

Publication only | Abstract: e24036 | Track: Symptoms and Survivorship, [Health Promotion](#)

**Authors:** Mercy Oduor, Kelvin Manyega, Therese Lotodo, Austin Okuku, Diana Namaemba, Lorraine Oyolo, John Oguda, **Terry A. Vik**; AMPATH Eldoret, Eldoret, Kenya; University of Jos, Jos, Nigeria; Moi University School of Medicine, Eldoret, Kenya; AMPATH Oncology Institute, Eldoret, Kenya; Indiana University, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN

---

**Accelerated epigenetic age among HIV-infected Nigerian women with invasive cervical cancer.**

Publication only | Abstract: e17504 | Track: Gynecologic Cancer, [Cervical Cancer](#)

**Authors:** Jonah Musa, Kyeezu Kim, Yinan Zheng, **Lois B. Travis**, Demirkan Gursel, Olugbenga A. Silas, Fatimah Biade Abdulkareem, Godwin Imade, Alani Akanmu, Jian-Jun Wei, Masha Kocherginsky, Kwnag-Youn Kim, Firas Hazem Wehbe, Chad Achenbach, Rose Anorlu, Melissa A. Simon, Atiene Sagay, Folasade Ogunsola, Robert Murphy, Lifang Hou; University of Jos, Jos, Plateau, Nigeria; Northwestern University, Chicago, IL; Indiana University School of Medicine, Indianapolis, IN; Northwestern University, Feinberg School of Medicine, Chicago, IL; University of Jos, Jos, Nigeria; Lagos University Teaching Hospital, Idiaraaba, Lagos, Nigeria; University of Lagos, Lagos, Nigeria; Department of Pathology, Northwestern University, Feinberg Medical School, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Feinberg School of Medicine, Northwestern University, Chicago, IL

## TYPES OF PRESENTATIONS

---

The ASCO Scientific Program Committee chooses abstracts for the annual meeting and determines presentation format for each accepted abstract. The presentation types include:

**Oral Abstract Sessions:** This type of session includes 12-minute presentations of abstracts representing important clinical and translational research findings by topic category. Experts in the field are chosen to provide comprehensive 12-minute themed discussions of the findings from predetermined abstracts.

**Clinical Science Symposia:** Clinical Science Symposia provide foundational education on a specific topic combined with the presentation and discussion of relevant abstracts. Novel science is put into appropriate context, including assessment of applicability to clinical practice and the need for further research. Presenting authors give 12-minute oral presentations.

**Poster Discussion Sessions:** Each track-based poster discussion session is 90 minutes and highlights 12 abstracts from the poster session held earlier in the day. Four invited discussants each provide a 12-minute discussion placing the selected abstracts in context, with a focus on how the findings apply to clinical practice and future research.

**Poster Sessions:** Selected abstracts are grouped by topic and displayed on poster boards for 3 hours. The Poster Sessions include Trials in Progress abstracts within each track, designed to facilitate awareness of open, ongoing clinical trials of any phase.

**Publication-Only Abstracts:** Quality abstracts that are not selected by the ASCO Scientific Program Committee for presentation at the Annual Meeting may be chosen for inclusion online in the ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement.

*Source: 2021 ASCO Annual Meeting, <https://conferences.asco.org/am/abstract-selection-process-presentations>*